Bacterial infections in HIV: The extent and nature of the problem

International Journal of STD and AIDS

Volumn 8, Issue 1, 1997, Pages 5-15

  Brettle, R P ^a,b  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

bacterial infection; leukopenia; neutropenia

Indexed keywords

ANTIBIOTIC AGENT; CHLORAMPHENICOL; CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PNEUMOCOCCUS VACCINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BACTERIAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPENIA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; BACTERIAL INFECTIONS; HUMANS; NEUTROPENIA; PHAGOCYTOSIS;

EID: 0031035292     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462971918698     Document Type: Review

References (105)

1. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41(RR-17):1-19
2. Centers for Disease Control. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections. MMWR 1986;35:334-9
3. Brettle RP. Human immunodeficiency virus: The Edinburgh Epidemic. MD Thesis, University of Edinburgh, 1994
4. Zon L, Groopman JE. Hematological manifestations of HIV. Semin Hematol 1988;25:208-18
5. Cooper DA, Gatell JM, Kroon S, et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts of greater than 400 per cubic millimeter. NEJM 1993;329: 297-303
6. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic HIV infection. NEJM 1990;322:941-9
7. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81
8. Treacy M, Lai L, Costello C, Clark A. Peripheral blood and bone marrow abnormalities in patients with HIV-related disease. Br J Haematol 1987;65:289-94
9. Murphy MF, Metcalfe P, Waters AH, et al. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol 1987;66:337-40
10. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of AZT in the treatment of patients with AIDS and ARC. NEJM 1987;317:192-7
11. Flegg PJ, Laing RBS, Lee C, et al. Disseminated disease due to Mycobacterium avium complex in AIDS. QJM 1995;88:617-26
12. Tumbarello M, Tacconelli E, Caponera S, Cauda R, Ortona L. The impact of bacteraemia in HIV infection. Nine years experience in a large Italian university hospital. J Infect 1995;31:123-31
13. Fischl M, Parker CB, Pettinelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immune deficiency syndrome. NEJM 1990;323:1009-14
14. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in HIV infection. NEJM 1992;327:581-7
15. Cooper DA, Pehrson PO, Pederson C, et al. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS or ARC: a double blind randomized trial. AIDS 1993;7:197-207
16. Shaunak S, Bartlett JA. Zidovudine induced neutropenia: are we too cautious. Lancet 1989;ii:91-2
17. Cooper DA, Pehrson O, Pederson C, et al. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and ARC: a double blind randomized trial. AIDS 1993;7:197-207
18. Kahn J, Lagakos S, Richman DR, et al. A controlled trial comparing continued zidovudine with didanosine in HIV infection. NEJM 1992;327:581-7
19. Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with HIV infection. NEJM 1994;330:657-62
20. Jacobsen MA. Ganciclovir therapy for opportunistic cytomegalovirus disease in AIDS. In: Volberding P, Jacobsen MA, eds. AIDS Clinical Review 1990. New York: Marcel Dekker, 1990
21. Jacobsen MA, de Miranda P, Gordon SM, Blum MR, Volberding P, Mills J. Prolonged pancytopenia due to combined ganciclovir and zidovudine therapy. J Infect Dis 1988;158:489-90
22. Ellis M, Gupta S, Galant S, et al. Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation. J Infect Dis 1988;158:1268-76
23. Pitrak DL, Bak PM, DeMarais P, Novak RM, Anderson BR. Depressed neutrophil superoxide production in HIV infection. J Infect Dis 1993;167:1406-10
24. Dukes CS, Matthews TJ, Weinberg JB. Human immunodeficiency virus type 1 infection of human monocytes and macrophages does not alter their ability to generate an oxidative burst. J Infect Dis 1993;168:459-62
25. Corazzo GR, Zoli G, Ginaldi L, et al. Tuftsin deficiency in AIDS. Lancet 1991;337:12-13
26. Janoff EN, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection. Ann Intern Med 1992;117:314-24
27. Klein RS, Selwyn PA, Maude D, Pollard C, Freeman K, Schiffman G. Response to pneumococcal vaccine among asymptomatic heterosexual partners of persons with AIDS and intravenous drug users infected with HIV. J Infect Dis 1989;160:826-31
28. Rodriguez-Barradas MC, Musher DM, Lahart C, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of HIV-infected subjects with 23 valent pneumococcal vaccine. J Infect Dis 1992;165:553-6
29. Stoneburner RL, Des Jarlais DC, Benezra D, et al. A larger spectrum of severe HIV-1 related disease in intravenous drug users in New York City. Science 1989;242:916-18
30. Haastrecht HJA, van dem Hoek AJAR, Coutinho RA. High mortality among HIV-infected injecting drug users without an AIDS diagnosis: implications for HIV infection epidemic modellers? AIDS 1994;8:363-6
31. Zaccarelli M, Gattari P, Rezza G, et al. Impact of HIV infection on non-AIDS mortality among Italian injecting drug users. AIDS 1994;8:345-50
32. Galli M, Musicco M for the COMCAT study group. Mortality of intravenous drug users living in Milan, Italy: role of HIV infection. AIDS 1994;8:1457-63
33. Jones ME, Brettle RP, Busuttil A, Inglis MH, Bell JE, Willocks L. Sudden death in HIV-infected drug user. Presumptive overdose in an HIV-positive narcotic addict. J Infect 1993;27:79-81
34. Bell JE, Busuttil A, Ironside JW, et al. Human immunodeficiency virus and the brain: investigations of virus load and neuropathologic changes in pre-AIDS subjects. J Infect Dis 1993;168:818-24
35. Eskild A, Magnus P, Sohlberg C, et al. Slow progression to AIDS in intravenous drug users infected with HIV in Norway. J Epidemiol Comm Health 1994;48:383-7
36. Beck EJ, Kennelly J, McKevitt C, et al. Changing presentation and survival, service utilisation and costs for AIDS patients: insights from a London referral centre. AIDS 1994;8: 379-84
37. Beck EJ, Kennelly J, McKevitt C, et al. Changing use of hospital services and costs at a London AIDS referral centre, 1983-1989. AIDS 1994;8:367-77
38. Nageswaran A, Kinghorn GR, Shen RN, Priestley CJF, Kyi TT. Hospital service utilization by HIV/AIDS patients and their management cost in a provincial genitourinary medicine department. Int J STD AIDS 1995;6:336-44
39. Brettle RP, Atkinson FI, Wilcock J, et al. Hospital and hospice resource use of HIV-positive patients in Edinburgh. Int J AIDS STDs (submitted)
40. Willocks L, Cowan FM, Brettle RP, Emmanuel FXS, Flegg PJ, Burns S. The spectrum of chest infections in HIV-positive patients in Edinburgh. J Infect 1992;24:37-12
41. Selwyn PA, Hartel D, Wasserman W, Drucker E. Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in New York City methadone maintenance program. Am J Public Health 1989;79:1358-62
42. Selwyn PA, Alcabes P, Hartel D, et al. Clinical manifestations and predictors of disease progression in drug users with HIV infection. N Engl J Med 1992;327:1697-703
43. Caiaffa WT, Graham NMH, Vlahov D. Bacterial pneumonia in adult populations with HIV infection. Am J Epidemiol 1993;138:909-22
44. Brettle RP, Foreman A, Povey S. Clinical features of early HIV in the Edinburgh City hospital cohort. Int J STD AIDS 1996;7:110-16
45. Mientjes GH, van Ameijden EJ, van den Hoek AJAR, Coutinho RA. Increasing morbidity without rise in non-AIDS mortality among HIV-infected intravenous drug users in Amsterdam. AIDS 1992;6:207-12
46. Robertson JR, Bucknall ABV, Welsby PD, et al. An epidemic of AIDS-related virus (HTLV-III/LAV) infection amongst intravenous drug abusers in a Scottish general practice. BMJ 1986;292:527-30
47. Brettle RP, Nelles B. Special problems of injecting drug misusers. Br Med Bull 1988;44:149-60
48. Haw S, Liddell D. Drug problems in Edinburgh district. Report of the SCODA Fieldwork Survey 1987. London: SCODA
49. Burns S, Brettle RP, Gore SM, Peutherer J, Robertson JR. Epidemiology of injection drug use related HIV in Edinburgh: a historical perspective and new insight on past HIV incidence from the retrospective HIV testing of stored sera. J Infect 1995 (in press)
50. Brettle RP, McNeil AJ, Gore SM, Bird AG, Richardson A. Analysis of enrolment, progression, survival, mortality and descriptive covariates in the Edinburgh City hospital cohort. QJM 1995;88:479-91
51. Bisset C, Jones G, Davidson J, et al. Mobility of injection drug users and transmission of HIV. Lancet 1989;ii:44
52. Selwyn PA, Feingold AR, Hartel D, et al. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS 1988;2:267-72
53. Simberkoff MS, El-Sadr W, Schiffman G, Rahal JJ Jr. Streptococcus pneumoniae infections and bacteraemia in patients with acquired immune deficiency syndrome, with report of a pneumococcal vaccine failure. Am Rev Respirat Dis 1984;130:1174-6
54. Polsky B, Gold JW, Whimbey E, et al. Bacterial pneumonia in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1986;104:38-41
55. Centers for Disease Control, Editorial. Increase in pneumonia mortality among young adults and the HIV epidemic - New York City, United States. MMWR 1988;37(38): 593-6
56. Redd SC, Rutherford III GW, Sande MA, et al. The role of HIV infection in pneumococcal bacteraemia in San Francisco residents. J Infect Dis 1990; 162:1012-17
57. Falco V, Fernandez de Sevilla T, Alegre J, et al. Bacterial pneumonia in HIV-infected patients: a prospective study of 68 episodes. Eur Respir J 1994;7:235-9
58. Manfredi R, Costigliola P, Ricchi E, Chiodo F. Sepsisbacteraemia and other infections due to non-opportunistic bacterial pathogens in a consecutive series of 788 patients hospitalized for HIV infection. Clin Ter 1993;143:279-90
59. Klimas NG, Blaney NT, Morgan RO, et al. Immune function and anti-HTLV-I/II status in anti-HIV-1 negative intravenous drug users receiving methadone. Am J Med 1991;90:163-70
60. Tubaro E, Borelli G, Croce C, Cavallo G, Santiangeli C. Effect of morphine on resistance to infection. J Infect Dis 1983;148:656-6
61. Anonymous. Editorial: opiates, opioid peptides, and immunity. Lancet 1984;i:774-5
62. Arora PK, Fride E, Petitto J, Waggie K, Skolnick P. Morphine-induced modulation of the immune system: implications for AIDS. IV International Conference on AIDS, 13-16 June 1988, Stockholm. Sweden: Stockholm, Abstract 8021
63. Caiaffa WT, Vlahov D, Graham NMH, et al. Drug smoking, Pneumonocystis carinii pneumonia and immunosupression increases the risk of bacterial pneumonia in HIV-seropositive injection drug users. Am J Respir Crit Care Med 1994;150:1493-8
64. Gilks GF, Brindle RJ, Otieno LS, et al. Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya. Lancet 1990;336:545-9
65. Hoekman P, Van De Perre P, Nelissen J, Kwisanga B, Bogaerts J, Kanyangabo F. Increased frequency of infection after open reduction of fractures in patients who are seropositive for HIV. J Bone Joint Surg 1991;73A:675-9
66. Pallangyo K, Hakanson A, Lema L, et al. High HIV seroprevalence and increased HIV-associated mortality among hospitalized patients with deep bacterial infections in Dar es Salaam, Tanzania. AIDS 1992;6:971-6
67. Klein RS, Selwyn PA, Maude D, Pollard C, Freeman K, Schiffman G. Response to pneumococcal vaccine among symptomatic heterosexual partners of persons with AIDS and intravenous drug users infected with HIV. J Infect Dis 1989;160:826-32
68. Parkin JM, Helbert M, Hughes CL, Pinching AJ. Immunoglobulin G subclass deficiency and susceptibility to pyogenic infections in patients with AIDS-related complex and AIDS. AIDS 1989;3:37-9
69. Hickey MM, Shanson DC. Septicaemia in patients with and without AIDS at Westminster Hospital, London. J Infect 1993;27:243-50
70. Polsky B, Gold JWM, Whimbey E, et al. Bacterial pneumonia in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1986;104:38-41
71. Steinhart R, Reingold AL, Taylor F, Anderson G, Wenger JD. Invasive Haemophilus influenzae infections in men with HIV infection. JAMA 1992;268:3350
72. Pesola GR, Charles A. Pneumococcal bacteraemia with pneumonia - mortality in AIDS. Chest 1992;101:150-5
73. Laing RBS, Wardrop PJC, Welsby PDW, Brettle RP. Stridor in patients with HIV infection. J Laryngol Otol 1995 (in press)
74. Lucente FE. Otolaryngologic aspects of AIDS. Med Clin N Am 1991;75:1389-98
75. Celum CL, Chaisson RE, Rutherford GW, Barnhart JL, Echenberg DF. Incidence of salmonellosis in patients with AIDS. J Infect Dis 1987;156:998-1002
76. Hoepelman AIM, van Buren M, van den Broek J, Borleffs JCC. Bacteriuria in men infected with HIV-1 is related to their immune status (CD4+ cell count). AIDS 1992;6:179-84
77. De Pinho AMF, Lopes GS, Ramos-Filho CF, et al. Urinary tract infection in men with AIDS. Genitourin Med 1994;70:30-4
78. Evans JK, McOwan A, Hillman RJ, Forster GE. Incidence of symptomatic urinary tract infections in HIV-seropositive patients and the use of co-trimoxazole as a prophylaxis against Pneumocystis carinii pneumonia. Genitourin Med 1995;71:120-22
79. Peruzzi WT, Shapiro BA, Noskin GA, et al. Concurrent bacterial lung infection in patients with AIDS. Chest 1992;101:1399-403
80. Nichols L, Balogh K, Silverman M. Bacterial infections in AIDS. Am J Clin Pathol 1989;92:787-90
81. Fichtenbaum CJ, Claibourne Dunagan W, Powderly WG. Bacteraemia in hospitalized patients infected with HIV: a case control study of risk factors and outcome. J AIDS 1995;8:51-7
82. Martin J, Brimacombe J. Chromobacterium violaceum septicaemia: the intensive care management of two cases. Anaesth Intensive Care 1992;20:88-90
83. Perkocha LA, Geaghan SM, Yen TSB, et al. Clinical and pathological features of bacillary peliosis hepatitis in association with HIV infection. N Eng J Med 1990;323:1581-6
84. Relman DA, Loutit JS, Schmidt TM, Falkow S, Tompkins LS. The agent of bacillary angiomatosis - an approach to the identification of uncultured pathogens. New Engl J Med 1990;3231573-80
85. Koehler JE, Quinn FD, Berger T, LeBoit PE, Tappero JW. Isolation of Rochalimea species from cutaneous and osseous lesions of bacillary angiomatosis. N Engl J Med 1992;327: 1625-31
86. Fiaccadori F, Elia GF, Calzetti C, Degli Antoni A, Magnani G. Rhodococcus equi infection in HIV-positive patients: report of 5 cases and literature overview. Monaldi Arch Chest Dis 1994;49:380-8
87. Jablonowski H, Armbrecht C, Mauss S, et al. Rhodococcus equi pneumonia in an HIV-infected patient. Bildgebung 1994;61:206-9
88. Paddock CD, Suchard DP, Grumbach KL, et al. Brief report: fatal seronegative ehrlichiosis in a patient with HIV infection. N Engl J Med 1993;329:1164-7
89. Bizet C, Mechali D, Rocourt J, Fraisse F. Listeria monocytogenes bacteraemia in AIDS. Lancet 1989;i:501
90. Sathapatayavongs B, Damrongkitchaiporn S, Saengditha P, et al. Disseminated penicilliosis associated with HIV infection. J Infect 1989;19:84-5
91. Li PCK, Tsui MS, Ma KF. Penicillium marneffei: indicator disease for AIDS in South East Asia. AIDS 1992;6:240-1
92. Rokiah L, Ng KP, Soo-Hoo TS. Penicillium marneffei infection in an AIDS patient - a first case report from Malaysia. Med J Malaysia 1995;50:101-4
93. Ong KR, Stavropoulos C, Inada Y. Babesiosis, asplenia and AIDS. Lancet 1990;ii:112
94. Gradon JD, Timpone JG, Schnittman SM. Emergence of unusual opportunistic pathogens in AIDS: a review. Clin Infect Dis 1992;15:134-57
95. Berger TG, Kaveh S, Becker D, Hoffman J. Cutaneous manifestations of pseudomonas infection in AIDS. J Am Acad Dermatol 1995;32:279-80
96. Willocks LJ, Vithayathil K, Tang A, Noone A. Pneumococcal vaccine and HIV infection: report of a vaccine failure and reappraisal of its value in clinical practice. Genitorurin Med 1995;71:71-2
97. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995;86:1082-9
98. Groopman JE. Antiretroviral therapy and immunomodulators in patients with AIDS. Am J Med 1991;90:18s-21s
99. Gendalman HE, Orenstein JM, Martin MA, et al. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1 treated macrophages. J Exp Med 1988;167:1428-41
100. Perno CF, Yarchoan R, Cooney DA, et al. Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GMCSF) potentiates viral production yet enhances the antiviral effect mediated by 3′-azido2′3′-thymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med 1989;169:933-51
101. Kalter DC, Nakamura M, Turpin JA, et al. Enhanced HIV replication in macrophage colony-stimulating factor-treated macrophages. J Immunol 1991;146:298-306
102. Davison FD, Kaczmarski RS, Pozniak A, Mufti GJ, Sutherland S. Quantification of HIV by PCR in monocytes and lymphocytes in patients receiving antiviral treatment and low dose recombinant granulocyte macrophage colony stimulating factor. J Clin Pathol 1994;47:855-7
103. Krown SE, Paredes J, Bundow D, Polsky B, Gold JWM, Flomenberg. Interferon-α, zidovudine and granulocyte-macrophage colony stimulating factor: a phase I AIDS Clinical Trials Group Study in patients with Kaposi's sarcoma associated with AIDS. J Clin Oncol 1992;10:1344-51
104. Kaczmarski RS, Pozniak A, Lakhani A, Harvey E, Mufti GJ. A pilot study of low-dose recombinant granulocyte-macrophage colony-stimulating factor in chronic neutropenia. Br J Haematol 1993;84:338-40
105. Hengge UR, Brockmeyer NH, Goos M. Granulocyte colony-stimulating factor treatment in AIDS patients. Clin Invest 1992;70(10):922-6